NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks.
In the past week, the Nordic biotech and healthcare stocks declined 1.1%. Most notably, Zealand Pharma initiated two new phase 3 studies in MASH with Survodutide, while FDA approval for Dasiglucagon was delayed. Further, Acarix got a new order, Genmab new price targets, Saniona received a milestone payment, and Biosergen completed enrollment of a trial with BSG005.
Only 4 of the 22 Danish biotech companies had a positive share price development the past week and 10 companies have had a positive share price performance year-to-date. Obesity continues to drive the best performances with Gubra, Zealand Pharma, and Pila Pharma having strong YTD performance. Five Danish healthcare stocks with +100% YTD return.
Danish company news
Multi-Location Customer Places Order of the Acarix CADScor System with Goal to Scale Usage (Link)
No news the past week
Biosergen Completes Enrollment of First Cohort in BSG005 Proof-of-Concept Trial (Link)
No news the past week
No news the past week
Curasight A/S announces last day of trading in BTU and first day of trading in warrant series TO2 and TO3 (Link)
No news the past week
Strong validation of Evaxion’s AI-Immunology™ platform in multiple clinical trials (Link)
No news the past week
FluoGuide A/S submits Clinical Trial Application for phase II trial in head and neck cancer (Link)
DNB Markets lowered their price target from DKK 2,600 to DKK 2,500, Redburn to DKK 2,899, Barclays to DKK 2,100 from DKK 2,500, and Cowen to DKK 2,000 from DKK 2,015
No news the past week
No news the past week
No news the past week
No news the past week
Saniona Initiates SAN711 Biomarker Study (Link)
Saniona Ion Channel Research Collaboration with Boehringer Ingelheim Reaches Milestone (Link)
No news the past week
No news the past week
No news the past week
Zealand Pharma announces that Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two Phase III trials in MASH for survodutide (Link)
Zealand Pharma provides U.S. regulatory update on dasiglucagon in congenital hyperinsulinism (Link)
No news the past week
No news the past week
Share price development – Danish stocks
On average, the Danish biotech and healthcare stocks delivered a negative return of 3.8%. Most notably, Zealand Pharma announced an FDA breakthrough therapy designation, and two phase III trials in Mash for Survodutide were initiated. However, the company also announced a delay in the approval of Dasiglyucagon in the U.S. The company got international awareness as well in CNBC (Link). Furthermore, Saniona initiated a biomarker study with SAN711 and received MEUR 0.5 after they reached a milestone as the partnership with Boehringer Ingelheim reached a milestone. Acarix got new orders, Biosergen completed enrollment of the first cohort in trial with BSG005, Evaxion saw additional validation of their AI platform, Fluoguide submitted an application for a phase II trial in head and neck cancer. Finally, Genmab got several new price targets.
Gubra continues to be the best-performing stock year-to-date with a return of 286%. Pila Pharma, Zealand Pharma, Cessatech, and Y-mAbs Therapeutic have also generated returns of over 100% in 2024.
Overview of share price development the past week, year-to-date, and the last twelve month
Nordic Biotech & Healthcare Developments
In the past week, the all-Nordic index Kapital Partner Nordic Healthcare Index (KPHC) fell 1.1% to 66,10. The index has had a strong performance since the beginning of October last year and it has now not only surpassed the KPNGX index but it has also joined the larger indices regarding performance. In the past 12 months, the KPHC index has thus had higher volatility but is now among the same performance as C25 and S30 – far better than the other Nordic growth exchange stocks.
Chart development for KPHC vs. C25, S30, and KPNGX indices the past year
Diagonal Bio became the winner for the second week in a row!
Diagonal Bio AB (99%) is developing a platform under the name Panviral to detect and diagnose small sections of pathogen genomes, such as viruses, bacteria, and fungi. In addition to the main business, service, and associated ancillary services are also offered. The company announced successful external validation of LAMPlify® for viruses in pigs and another pilot study is to come for LAMPify in horses.
Dignitana AB (46%) main focus is to develop, manufacture, and distribute medical aids that are primarily used as a scalp cooling system in chemotherapy treatment, where the purpose is to eliminate or greatly reduce hair loss. The stock rose 37% between 1 am and 2 am on October 9 without any news.
Spermosens AB (23%) specializes in the development of medical devices. The product portfolio is broad and includes products for male infertility and individually tailored fertility treatments. Research and development is conducted via its own technological platform that analyzes sperm quality, which is further used for medical data and potential fertilization.
Resources: Refinitiv Eikon, Cision, Nordnet & company websites
